Dr. Bogardus is a consultant specializing in pharmaceutical drug product development for small and large molecule drug candidates. With more than 40 years of experience in industry and academia, his work spans all phases of pharmaceutical research and development. At Bristol-Myers Squibb (BMS), Dr. Bogardus led groups focused on dosage form development, compound characterization, drug substance form selection, preformulation, early-phase and commercial formulation, and stability. He contributed to the global registration of drugs in oncology, antibacterials, antivirals, cardiovascular, and metabolic therapies. He also pioneered formulation development for biologics, working on internally discovered proteins and co-development projects. Dr. Bogardus played a key role in advancing numerous clinical trial candidates and several marketed drugs. He holds a bachelor’s in chemistry from the University of Kentucky and a master’s and doctorate in pharmaceutical chemistry from the University of Kansas.